Status | Study |
Recruiting |
Study Name: Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis Condition: Treatment Side Effects Date: 2017-03-09 Interventions: Drug: Lipid-lowering agents (Artovastatin) Artovastatin 20 mg /day, orally, 12 consecutive weeks. |
Completed |
Study Name: Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy Condition: Polymyositis Dermatomyositis Date: 2016-08-23 Interventions: Other: Patients with polymyositis / dermatomyositis recrui |
Recruiting |
Study Name: A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Condition: Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc Date: 2016-05-03 Interventions: Biological: MEDI7734 Three sub |
Active, not recruiting |
Study Name: A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia Condition: Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis Date: 2014-06-06 Interventions: Drug: Prograf oral Other Names: |
Recruiting |
Study Name: Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Condition: Dermatomyositis Polymyositis Date: 2014-01-17 Interventions: Drug: tocilizumab given at a d |
Completed |
Study Name: Epidemiological Study of Inflammatory Myopathies in a French Region Condition: Polymyositis Date: 2013-12-19 |
Completed |
Study Name: Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Condition: Dermatomyositis Polymyositis Date: 2013-07-05 Interventions: Drug: Adrenocorticotropic Hormone Gel H.P. Acthar Gel 80 units will be self-administered subcutaneously |
Completed |
Study Name: Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis Condition: Polymyositis Dermatomyositis Date: 2013-03-13 Interventions: Drug: Immunosuppressive Agents Patients in the cohort received medical treatment according to standard c |
Terminated |
Study Name: Efficacy and Tolerability of BAF312 in Patients With Polymyositis Condition: Polymyositis Date: 2013-02-01 Interventions: Drug: Placebo Drug: BAF312 |
Enrolling by invitation |
Study Name: Dermatomyositis and Polymyositis Registry Condition: Dermatomyositis Polymyositis Date: 2012-07-06 Interventions: Drug: Acthar Physicians will prescribe Acthar at their own discretion; however the recommended dose is 8 |